查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
RNA治疗药及RNA疫苗市场:各种模式，各分子类型，各治疗领域，各给药途径，各主要地区，主要加入企业:产业趋势全球预测，2023年～2035年
市场调查报告书
商品编码
1347906

RNA治疗药及RNA疫苗市场:各种模式，各分子类型，各治疗领域，各给药途径，各主要地区，主要加入企业:产业趋势全球预测，2023年～2035年

RNA Therapeutics Market & RNA Vaccines Market by Type of Modality, Type of Molecule, Therapeutic Areas, Route of Administration, Key Geographical Regions & Leading Players: Industry Trends & Global Forecasts, 2023-2035
出版日期: | 出版商: Roots Analysis | 英文 170 Pages | 商品交期: 最快1-2个工作天内

价格

下一代RNA疫苗和RNA疗法的市场状况比较集中，大型公司、中型公司和中小企业超过35家。其中 50% 成立于 2016 年至 2020 年期间，显示该治疗市场领域的初创活动很高。此外，超过 70% 的公司总部位于北美。在欧洲，英国正在成为参与下一代 RNA 疗法和 RNA 疫苗开发的公司的中心。

目前，超过 100 种下一代 RNA 疗法和 RNA 疫苗已获得批准或正在不同的开发阶段进行评估。此外，分别有 40% 和 32% 的候选药物正处于不同开发阶段，用于治疗传染病和肿瘤疾病。这些候选药物已成为治疗开发商中流行的标靶疗法。

近年来，随着医疗保健产业的进步，各种新药被开发出来。有趣的是，该行业正在评估下一代 RNA 疗法和 RNA 疫苗，它们正在成为针对多种适应症的标靶疗法。

自 2021 年以来，已註册 18 项临床试验来评估下一代 RNA 疗法和疫苗。其中，72% 是针对传染病的试验。这可能是由于行业参与者开发针对 COVID-19 的治疗方法的活动增加。有趣的是，其中 27% 的临床试验已进入开发后期（II 期及以上）。随着下一代 RNA 疗法和 RNA 疫苗进入临床开发轨道，预计市场在预测期内将以有利的复合年增长率成长。

RNA 疫苗引起了製药业的关注，特别是在 COVID-19 大流行期间，第一代基于 mRNA 的 COVID 疫苗获得了监管部门的批准。在 mRNA 疫苗出现之前，其他方法（例如反义 RNA、siRNA 和 RNA 适体）被评估为治疗剂。Gemcovac(R) 由 HDT Bio 开发，是第一种基于自扩增 mRNA (saRNA) 的新冠疫苗，于 2022 年 6 月在印度获得紧急使用授权。这种新冠疫苗目前正在美国、巴西和韩国进行临床试验。关键临床试验结果表明，与 Moderna 和辉瑞开发的新冠疫苗相比，Gemcovac(R) 的不良事件发生率要低得多。这种治疗的免疫反应与阿斯特捷利康开发的免疫反应相当。此外，Gemcovac(R) 以冻干粉末形式提供，因此需要储存在普通冰箱中。这种自扩增 mRNA 疫苗是皮内注射的，与许多肌肉注射的新冠疫苗不同。由于其高度稳定的结构、改进的治疗方案和低浓度给药，下一代 RNA 疗法和 RNA 疫苗正在成为传统 RNA 方法的潜在替代品。

这场大流行极大地推动了基于 RNA 的疗法的发展。从那时起，行业利益相关者一直积极致力于开发持久且能够针对广泛治疗标靶的疗法，并使用各种方法开发下一代 RNA 疗法和 RNA 疫苗。

由于人们对研发活动的兴趣日益浓厚，以及对罕见肿瘤疾病有效治疗的需求不断增长，下一代 RNA 疗法和 RNA 疫苗市场预计将在预测期内（2026-2026 年）增长。预计到2035年，复合年增长率(CAGR) 将超过50%）。具体来说，从分子类型来看，全球下一代 RNA 疗法和 RNA 疫苗市场预计将由自我扩增 mRNA 推动。同样，从治疗领域来看，针对癌症和肺部疾病的 RNA 疗法和 RNA 疫苗预计将主导市场。

此外，到 2035 年，近 94% 的市占率将由北美公司占。然而，值得注意的是，亚太地区下一代RNA疗法和RNA疫苗市场预计在预测期（2030-2035年）将以更高的复合年增长率成长。

本报告提供全球RNA治疗药及RNA疫苗市场相关调查，提供市场概要，以及各种模式，各分子类型，各治疗领域，各给药途径，各主要地区，按主要加入企业趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 序文

第2章 调查手法

第3章 经济以及其他的计划特有的考虑事项

第4章 摘要整理

第5章 简介

第6章 市场形势

  • RNA治疗药及RNA疫苗:治疗的大气候
  • RNA治疗药及RNA疫苗:临床阶段的治疗形势
  • RNA治疗药及RNA疫苗:治疗开发商的形势
  • RNA治疗药及RNA疫苗:循环RNA治疗的形势
  • RNA治疗药及RNA疫苗:自我放大RNA治疗的形势

第7章 技术形势

  • RNA治疗药及RNA疫苗:下一代RNA技术的形势
  • RNA治疗药及RNA疫苗:下一代RNA技术/平台开发商的形势

第8章 药物简介

  • gemukovatsu
  • ATYR1923
  • ARCT-154
  • GRT-C901
  • VLPCOV-01
  • AVX901
  • MTL-CEBPA+Sorafenib
  • 石板瓦

第9章 临床试验的分析

  • 分析调查手法主要的参数
  • RNA治疗药及RNA疫苗:临床试验分析

第10章 专利分析

  • 分析调查手法主要的参数
  • RNA治疗药及RNA疫苗:专利分析
  • RNA治疗药及RNA疫苗:专利基准分析
  • RNA治疗药及RNA疫苗:专利评估分析

第11章 伙伴关係和合作

第12章 资金筹措和投资的分析

第13章 大型製药公司的配合措施

  • RNA治疗药及RNA疫苗:大型製药公司的配合措施

第14章 RNA治疗药及RNA疫苗市场全体，2023年年～2035年

第15章 RNA治疗药及RNA疫苗市场全体，各种模式

第16章 RNA治疗药及RNA疫苗市场全体，各分子类型

第17章 RNA治疗药及RNA疫苗市场全体，各治疗领域

第18章 RNA治疗药及RNA疫苗市场全体，各给药途径

第19章 RNA治疗药及RNA疫苗市场全体，各主要地区

第20章 RNA治疗药及RNA疫苗市场全体，各主要企业

第21章 结论

第22章 附录1:表格形式的资料

第23章 附录2:企业及组织的清单

Product Code: RA100454

INTRODUCTION

The global RNA Vaccines and RNA Therapeutics market is estimated to be worth over USD 1.1 billion in 2035 and is expected to grow at compounded annual growth rate (CAGR) of 50% during the forecast period (2026-2035).

In the past few years, RNA based therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions. In addition, they offer enhanced therapeutic and safety profiles as compared to traditional treatment approaches. However, there are some concerns associated with the highly unstable nature of such molecules and their delivery at adequate concentrations. Therefore, in order to address the challenges pertaining to the use of RNA therapeutics and RNA vaccines, several industry players have been engaged in the development / deployment of novel technologies for the design, development and manufacturing of next generation RNA-based therapeutics / vaccines, offering the healthcare sector a promising disease management recourse.

The next generation RNA therapeutics and RNA vaccines are modified treatment molecules aimed at specifically targeting and treating diseases that were earlier considered undruggable. Among these, innovative modalities, such as circular RNA (circRNA), endless RNA (eRNA), self activating RNA (sacRNA), self amplifying RNA (saRNA), self amplifying mRNA (samRNA), replicating RNA (repRNA) and transfer RNA (tRNA) have emerged as popular targeted therapeutics. The success of these next generation RNA therapeutics and RNA vaccines can be attributed to their structural stability, expression specificity, targeted delivery, non-immunogenic nature, high efficiency and ability to target a wide range of therapeutic modalities, including influenza, COVID-19 infection, breast cancer and interstitial lung disease, among others.

Further, owing to their self-replicating nature, such RNA-based therapies offer prolonged therapeutic effects at relatively low and less frequent doses, as compared to traditional methods.

Given the ongoing pace of innovation in this field, encouraging clinical trial results, accelerated approvals, and the continuous efforts of both industry and non-industry players, the next generation RNA vaccines and RNA therapeutics market is likely to witness significant growth during the forecast period.

SCOPE OF THE REPORT

"The RNA Vaccines and RNA Therapeutics Market: Distribution by Type of Modality (RNA Therapeutics and RNA Vaccines), Type of Molecule (replicating RNA, self amplifying RNA, self activating RNA, self amplifying mRNA and transfer RNA), Therapeutic Areas (Infectious Diseases, Oncological Disorders and Pulmonary Disorders), Route of Administration (Intradermal, Intramuscular and Intravenous), Key Geographical Regions (North America, Europe and Asia-Pacific) and Leading Players: Industry Trends and Global Forecasts, 2023-2035" report features an extensive study of the current market landscape, market size and future opportunities associated with the RNA vaccines and RNA therapeutics market, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.

Key takeaways of the RNA vaccines and RNA therapeutics market are briefly discussed below.

Current Market Landscape: Next Generation RNA Therapeutics and RNA Vaccines Offering Efficient Treatment Recourse

The next generation RNA vaccines and RNA therapeutics market landscape is concentrated with the presence of over 35 large, mid-sized and small companies. Of these, 50% of the companies were established during the period 2016-2020, indicating significant start-up activity in this therapeutic market segment. Examples of companies (established in 2019 and 2020, in alphabetical order) include Chimerna Therapeutics, Orna Therapeutics, Replicate Bioscience, Transine Therapeutics, VaxEquity, VLP Therapeutics and Ziphius Vaccines. Further, more than 70% of the companies are based in North America. Within Europe, the UK has emerged as the hub of players engaged in the development of next generation RNA therapeutics and RNA vaccines.

It is worth mentioning that, currently, over 100 next generation RNA therapeutics and RNA vaccines are either approved or being evaluated in various stages of development; of these, nearly 25% of the drug candidates are being evaluated in clinical trials. Further, 40% and 32% of the drug candidates are being investigated for the treatment of infectious diseases and oncological disorders, respectively, across different phases of development. These drug candidates have emerged as popular targeted therapy among therapy developers.

Recent advancements in the healthcare industry in the last few years have led to the development of various novel drug modalities. Interestingly, the industry is evaluating next generation RNA therapeutics and RNA vaccines, which have surfaced as possible targeted therapies for a wide range of therapeutic indications.

Clinical Trials Analysis: A number of RNA Therapeutics and RNA Vaccines are Being Evaluated in Clinical Trials

It is important to highlight that a therapeutic modality, ATYR1923, developed by aTyr Pharma, is currently being investigated in phase III, targeting Pulmonary Sarcoidosis. Recently, in August 2022, the drug received fast track designation from the USFDA. Over 1,160 clinical trial initiatives focused on various next generation drug modalities, such as circular RNA (circRNA), endless RNA (eRNA), self-activating RNA (sacRNA), self amplifying RNA (saRNA), self amplifying mRNA (samRNA), replicating RNA (repRNA) and transfer RNA (tRNA), long non coding RNA and others have been undertaken since 2019, indicating the substantial research efforts being made in this industry.

Since 2021, 18 clinical trials have been registered for the evaluation of next generation RNA therapeutics and vaccines. Of these, 72% of the trials were focused on infectious diseases. This can be attributed to the enhanced activity of industry players towards the development of therapies targeting COVID-19. Interestingly, 27% of these trials have advanced to the late stages of development (phase II and above). As the next generation RNA therapeutics and RNA vaccines move along the clinical development trajectory, we expect the market to grow at a favorable CAGR during the forecast period.

Self Amplifying mRNA Vaccines Offer Several Advantages Over the First Generation mRNA Vaccines

RNA vaccines have caught the attention of the pharmaceutical industry, specifically during the COVID-19 pandemic, when the first generation mRNA based COVID vaccine received approval from regulatory authorities. Prior to mRNA vaccines, other modalities, such as antisense RNA, siRNA and RNA aptamers were evaluated as therapeutics. Gemcovac®, developed by HDT Bio was the first self amplifying mRNA (saRNA) based COVID vaccine to receive emergency use approval in India, in June 2022. Notably, this COVID vaccine is currently being evaluated in clinical trials in the US, Brazil and South Korea. According to the pivotal trial results, Gemcovac® demonstrated a much lower rate of adverse events as compared to the COVID vaccine, developed by Moderna and Pfizer. The immunological response of the therapy was comparable to that developed by AstraZeneca. Additionally, Gemcovac® is supplied in lyophilized powder form and requires storage in a normal refrigerator. This self amplifying mRNA vaccine is delivered intradermally, unlike most of the COVID vaccines that are administered intramuscularly. Owing to their highly stable structure, enhanced therapeutic profile and low concentration administration, the next generation RNA therapeutics and RNA vaccines have emerged as a potential alternative to conventional RNA-based approaches.

Another player, Arcturus Therapeutics is developing the COVID vaccine using its proprietary self amplifying mRNA technology platform. In April 2023, its collaboration partner, Meiji Seika Pharma, submitted an NDA to commercialize the vaccine, ARCT-154, in Japan. The launch of more such self amplifying mRNA vaccines will drive the market growth over the forecast period.

Potential of tRNA Therapeutics is Being Explored by Few Key Companies

The pandemic offered a major thrust to RNA-based therapies. Since then, industry stakeholders are actively being engaged in the development of therapies that are long lasting and can target a wide range of therapeutic targets, giving rise to the development of next generation RNA therapeutics and RNA vaccines using various approaches.

One such approach involves the use of transfer RNA (tRNA), being engineered by US-based Alltrna, in order to correct gene code and ultimately gene expression. The company raised USD 50 million in Series A funding in 2020. However, Alltrna is not the sole company working on tRNA technology. Other companies include ReCode Therapeutics, ShapeTX, Tevard Biosciences and hC Bioscience. The current tRNA market landscape features the presence of close to ten therapies, of which, majority are still in early stages of development. These therapies are primarily being developed to target indications, such as Cystic Fibrosis, Duchenne Muscular Dystrophy and Pulmonary Sarcoidosis.

Circular RNA Therapeutics Market is Witnessing a number of Start Ups and Funding Activity

Circular RNA is a covalently bonded closed-loop RNA structure, engineered from linear RNAs by circularization. These structures confer higher stability to the RNA molecules, protecting the molecule from rapid degradation by exonucleases. Recently, the next generation RNA therapeutics and vaccines domain has witnessed the emergence of industry players engaged in the development of circular RNA therapies, owing to the vast potential and high stability of such therapies. Examples of some players include (in alphabetical order) Chimerna Therapeutics, Esperovax, Flagship Pioneering's Laronde, Ginkgo Bioworks, Orna Therapeutics, Ring Code Biotech, Circio and Therorna. Notably, since 2019, more than USD 380 million has been raised / invested by companies engaged in the development of circular RNA, reflecting significant funding activity for circular RNA-based therapies in this domain.

It is worth highlighting that industry players are actively collaborating with circular RNA therapy developers in order to support the discovery, development and delivery of circRNA molecules. For instance, Renagade Therapeutics has entered into a collaboration with Orna Therapeutics in order to support the delivery of circular RNA therapies being discovered by Orna Therapeutics. Considering the potential of these therapies, several industry stakeholders are actively engaging in the development of such therapeutics. The support from venture capitalists and big pharmaceutical companies will continue to drive the development of circular RNA therapeutics and market growth over the forecast period.

Key Trends in the Next Generation RNA Therapeutics and RNA Vaccines Market

Many stakeholders are undertaking initiatives to forge alliances with other industry / non-industry players. Of the strategic partnerships focused on next generation RNA therapeutics and RNA vaccines that have been inked since 2019, close to 22% of partnerships are research and development agreements, indicating that the stakeholders are actively engaged in research and development of these next generation RNA therapeutics and RNA vaccines. Interestingly, it was observed that many big pharma players, such as Merck, Gilead Sciences, AstraZeneca and others have partnered with several next generation RNA therapeutics and RNA vaccines players, in order to expand their respective portfolios. It is worth highlighting that a sum of $2.9 billion has been raised / invested by players engaged in the development of RNA therapeutics and RNA vaccines, indicating the interest of stakeholders in this market.

Given the inclination towards development of novel next generation RNA therapeutics and RNA vaccines, along with the engagement of big pharma players and high investments, we believe that the next generation RNA therapeutics and RNA vaccines market is likely to evolve at a rapid pace over the forecast period.

Next Generation RNA Vaccines and RNA Therapeutics Market Size: North America to Hold the Largest Market Share

Driven by the rising interest in R&D activities and growing demand for effective therapies for rare and oncological disorders, the next generation RNA therapeutics and RNA vaccines market is anticipated to witness an annualized growth rate (CAGR) of over 50%, during the forecast period (2026-2035). Specifically, in terms of type of molecule, the global market for next generation RNA therapeutics and RNA vaccines is anticipated to be driven by self amplifying mRNAs. Likewise, in terms of therapeutic area, the market is anticipated to be dominated by the RNA therapeutics and RNA vaccines targeting oncological disorders and pulmonary disorders.

In addition, close to 94% of the market share in 2035 is captured by the players based in North America. However, it is worth highlighting that the next generation RNA therapeutics and RNA vaccines market in Asia-Pacific is anticipated to grow at a higher CAGR, during the forecast period (2030-2035).

Recently, the increasing number of orphan and fast track designations granted by the regulatory authorities, such as the USFDA and the EMA, has intrigued interest and increased the confidence of the pharmaceutical industry in these novel targeted therapies. All the above factors will contribute to a healthy market growth of the next generation RNA therapeutics and RNA vaccines market during the forecast period.

Leading Next Generation RNA Therapeutics and RNA Vaccines Developers

Examples of key companies engaged in the next generation RNA therapeutics and RNA vaccines development (which have also been captured in this market report, arranged in alphabetical order) include Alphavax, Arcturus Therapeutics, Atyr Pharma, Flagship Pioneering, Forge Therapeutics, Gingko Bioworks, Gritstone Bio, HDT Bio, Laronde Therapeutics, MiNA Therapeutics, Orna Therapeutics, Recode Therapeutics, Renegade Therapeutics, Replicate Bioscience, Shape Therapeutics and VLP Therapeutics. This market report includes an easily searchable excel database of all the companies developing next generation RNA therapeutics and RNA vaccines, worldwide.

Recent Developments in the Next Generation RNA Vaccines and RNA Therapeutics Market

Several recent developments have taken place in the field of next generation RNA vaccines and RNA therapeutics, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we've outlined in our analysis.

  • In February 2023, Tevard Biosciences entered into a research and development agreement with Vertex Pharmaceuticals for the development of novel tRNA based therapies, intended for the treatment of Duchenne Muscular Dystrophy.
  • In January 2023, Esperovax entered into a product development agreement with Gingko Bioworks for the development of circular RNA therapeutics, specifically targeting colorectal cancer.
  • Further, in January 2023, HDT Bio entered into a technology utilization agreement with the Pan African Cancer Research Institute (PACRI), in order to develop self-amplifying RNA vaccines and therapeutics.

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:

  • A preface providing an introduction to the full report, RNA Therapeutics and RNA Vaccines Market, 2023-2035.
  • An outline of the systematic research methodology adopted to conduct the study on next generation RNA therapeutics and RNA vaccines market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
  • An overview of economic factors that impact the overall next generation RNA therapeutics and RNA vaccines market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • An executive summary of the insights captured during our research, offering a high-level view of the current state of the next generation RNA therapeutics and RNA vaccines market and its likely evolution in the mid-to-long term.
  • A brief introduction to the next generation RNA therapeutics and RNA vaccines, highlighting their historical background, as well as information on their types, key aspects, key challenges and the advantages of using next generation RNA modalities.
  • A detailed assessment of the market landscape of more than 100 next generation RNA therapeutics and RNA vaccines that are either approved or being evaluated in different stages of development, based on several relevant parameters, such as type of modality (therapeutics and vaccines), type of molecule (saRNA, circRNA, tRNA, sacRNA, ARC, SINEUPs, eRNA and lamRNA), type of delivery vehicle (lipid nanoparticles, viral vectors, non-lipid nanoparticles, non-viral vectors and polymers), phase of development (discovery, preclinical, phase I, phase I / II, phase II, phase II / III, phase III and emergency use approval), therapeutic area (infectious diseases, oncological disorders, genetic disorders, neurological disorders, immunological disorders and other disorders). Further, the chapter features analysis on key niche market segments (circRNA and saRNA). In addition, the chapter features analysis of various next generation RNA therapeutic and RNA vaccine developers, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of therapies).
  • A detailed assessment of the market landscape of more than 35 technologies that are being developed / deployed to support the development of next generation RNA therapeutics and RNA vaccines, based on several relevant parameters, such as class of molecule (therapeutics and vaccines), type of molecule (saRNA, circRNA, tRNA, sacRNA, ARC, SINEUPs, eRNA and lamRNA), capabilities of the technology (development, delivery, research and discovery, design and manufacturing), therapeutic area (oncological disorders, infectious diseases, genetic disorders, neurological disorders, immunological disorders, cardiovascular disorders, inflammatory disorders, ophthalmic disorders, rare disorders, pulmonary disorders, unspecified and other disorders) and highest phase of development (discovery, preclinical, clinical and commercial). In addition, the chapter features analysis of various next generation RNA therapeutic and RNA vaccine technology developers, based on their year of establishment, company size, location of headquarters and operational model.
  • Elaborate profiles of drug candidates that are in advanced stages of development (Phase II, III and above). Each drug profile features details on its developer, drug overview, clinical trial information, clinical trial endpoints, clinical trial results and estimated sales.
  • An in-depth analysis of completed and ongoing clinical trials of various next generation RNA therapeutics and RNA vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, patients enrolled, type of sponsor, therapeutic area, study design, leading organizations (in terms of number of trials), focus area and geography.
  • An in-depth analysis of patents related to next generation RNA therapeutics and RNA vaccines, filed / granted, since 2019, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), patent publication year, patent jurisdiction, CPC symbols, emerging focus areas, patent age, leading industry / non-industry players (in terms of number of patents filed / granted), and patent valuation.
  • An in-depth analysis of partnerships that have been inked between various stakeholders, since 2019, based on several relevant parameters, such as the year of partnership, type of partnership, type of molecule, focus of partnership, purpose of partnership, therapeutic area and most active players (in terms of number of partnerships). It also highlights the regional distribution of partnership activity in this market.
  • A detailed analysis of various investments made by companies engaged in this industry, since 2019, based on several relevant parameters, such as year of funding, type of funding (grants, seed, venture capital, initial public offering, secondary offerings, private equity and debt financing), type of molecule, amount invested, geography, purpose of funding, stage of development, therapeutic area, most active players (in terms of number and amount of funding instances) and leading investors (in terms of number of funding instances).
  • An in-depth analysis of the various next generation RNA therapeutics and RNA vaccines focused initiatives undertaken by big pharma players, based on several relevant parameters, such as number of initiatives, year of initiative, type of initiative, purpose of initiative, focus of initiative and location of headquarters of the big pharma players.

One of the key objectives of this market report was to estimate the current market size and the future growth potential of the next generation RNA therapeutics and RNA vaccines over the forecast period. Based on several parameters, such as region-specific adoption rates and expected prices of such modalities, we have developed informed estimates of the likely evolution of the next generation RNA vaccines and RNA therapeutics market over the forecast period 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of modality (therapeutics and vaccines), type of molecule (repRNA, saRNA, sacRNA, samRNA and tRNA), therapeutic area (infectious diseases, oncological disorders and pulmonary disorders), route of administration (intradermal, intramuscular and intravenous), key geographical regions (North America, Europe and Asia-Pacific) and leading players. In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry's evolution.

All actual figures have been sourced and analyzed from publicly available information forums and secondary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this market report has been gathered via secondary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary sources of information.

KEY QUESTIONS ANSWERED

Question 1: What are RNA-based therapeutics?

Answer: RNA-based molecules are a class of therapeutics that utilize RNA molecules for specifically targeting genes in order to regulate their function and expression. The altered gene expression aids in the management of several disease indications by producing the desired therapeutic effect.

Question 2: What is self replicating RNA mechanism? What are self-amplifying mRNA vaccines?

Answer: The self replicating property of RNA molecules enables them to create multiple copies of themselves within the cell without using additional cellular machinery, such as proteins and DNA. The mechanism involves the use of a short RNA strand as the template guide to synthesize a complementary copy of itself, thereby generating a new RNA molecule. The two new molecules then segregate to act as the template guides for further replication.

Question 3: What are self-amplifying mRNA vaccines?

Answer: Self-amplifying mRNA vaccines utilize a strand of messenger RNA designed to self-replicate and elicit a sustained immune response when administered to the human body. Owing to the self-replicating nature, the vaccine would not require frequent administration and would lead to a higher expression of proteins even at low dose concentration.

Question 4: Are RNA-based therapies approved by the FDA?

Answer: RNA-based therapies are continuously being evaluated in clinical trials for their safety and efficacy in the treatment of a wide range of therapeutic indications. It is worth noting that the first clinical trial of an mRNA-based vaccine was conducted in 2008. However, the first mRNA vaccine received the FDA approval for the treatment of COVID in 2021.

Question 5: What RNA drugs are FDA approved?

Answer: Interestingly, close to 10 RNA therapeutics have been approved till date. Of these, the primary types of therapies include those based on antisense oligonucleotides and small interfering RNA molecules. Further, Gemcovac®, a self amplifying RNA vaccine, has been granted emergency use approval as a COVID vaccine in India.

Question 6: How big is the next generation RNA vaccines and RNA therapeutics market?

Answer: The market size for the next generation RNA therapeutics and RNA vaccines market is estimated to be USD 1.1 billion in 2035.

Question 7: What is the likely market growth rate (CAGR) for the next generation RNA vaccines and RNA therapeutics market?

Answer: The market size for next generation RNA therapeutics and RNA vaccines is projected to grow at an annualized rate (CAGR) of ~50%, during the forecast period (2026-2035).

Question 8: Who are the leading companies in the next generation RNA therapeutics and RNA vaccines market?

Answer: Some of the leading companies engaged in the next generation RNA therapeutics and RNA vaccines development (which have also been captured in this market report, arranged in alphabetical order) include Arcturus Therapeutics, Flagship Pioneering, Forge Therapeutics, Gingko Bioworks, Laronde Therapeutics, Orna Therapeutics, Recode Therapeutics, Renegade Therapeutics, Replicate Bioscience and Shape Therapeutics.

CHAPTER OUTLINES

  • Chapter 1 is a preface providing an overview of the full report, RNA Therapeutics and RNA Vaccines Market, 2023-2035.
  • Chapter 2 is an outline of the systematic research methodology adopted to conduct the study on next generation RNA therapeutics and RNA vaccines market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
  • Chapter 3 is an overview of economic factors that impact the overall next generation RNA therapeutics and RNA vaccines market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • Chapter 4 is an executive summary of the key insights captured during our research, offering a high-level view of the current state of the next generation RNA therapeutics and RNA vaccines market and its likely evolution in the mid-to-long term.
  • Chapter 5 provides a general overview of the next generation RNA therapeutics and RNA vaccines, highlighting their historical background, as well as information on their types, key aspects, key challenges and the advantages of using next generation RNA modalities.
  • Chapter 6 provides information on more than 100 next generation RNA therapeutics and RNA vaccines that are either approved or being evaluated in different stages of development, based on several relevant parameters, such as type of modality (therapeutics and vaccines), type of molecule (saRNA, circRNA, tRNA, sacRNA, ARC, SINEUPs, eRNA and lamRNA), type of delivery vehicle (lipid nanoparticles, viral vectors, non-lipid nanoparticles, non-viral vectors and polymers), phase of development (discovery, preclinical, phase I, phase I / II, phase II, phase II / III, phase III and emergency use approval), therapeutic area (infectious diseases, oncological disorders, genetic disorders, neurological disorders, immunological disorders and other disorders). Further, the chapter features analysis on key niche market segments (circRNA and saRNA). In addition, the chapter features analysis of various next generation RNA therapeutic and RNA vaccine developers, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of therapies).
  • Chapter 7 provides information on more than 35 technologies that are being developed / deployed to support the development of next generation RNA therapeutics and RNA vaccines, based on several relevant parameters, such as class of molecule (therapeutics and vaccines), type of molecule (saRNA, circRNA, tRNA, sacRNA, ARC, SINEUPs, eRNA and lamRNA), capabilities of the technology (development, delivery, research and discovery, design and manufacturing), therapeutic area (oncological disorders, infectious diseases, genetic disorders, neurological disorders, immunological disorders, cardiovascular disorders, inflammatory disorders, ophthalmic disorders, rare disorders, pulmonary disorders, unspecified and other disorders) and highest phase of development (discovery, preclinical, clinical and commercial). In addition, the chapter features analysis of various next generation RNA therapeutic and RNA vaccine technology developers, based on their year of establishment, company size, location of headquarters and operational model.
  • Chapter 8 presents elaborate profiles of drug candidates that are in the advanced stages of development (Phase II, III and above). Each drug profile features details on its developer, drug overview, clinical trial information, clinical trial endpoints, clinical trial results and estimated sales.
  • Chapter 9 presents an in-depth analysis of completed and ongoing clinical trials of various next generation RNA therapeutics and RNA vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, patients enrolled, type of sponsor, therapeutic area, study design, leading organizations (in terms of number of trials), focus area and geography.
  • Chapter 10 provides in-depth analysis of patents related to next generation RNA therapeutics and RNA vaccines, filed / granted, since 2019, based on type of patent (granted patents, patent applications and others), patent publication year, patent jurisdiction, CPC symbols, emerging focus areas, patent age, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation.
  • Chapter 11 presents an in-depth analysis of partnerships that have been inked between various stakeholders since 2019, based on various parameters, such as the year of partnership, type of partnership, type of molecule, focus of partnership, purpose of partnership, therapeutic area and most active players (in terms of number of partnerships). The chapter also highlights the regional distribution of partnership activity in this market.
  • Chapter 12 features an in-depth analysis of various investments made by companies engaged in this industry, since 2019, based on several relevant parameters, such as year of funding, type of funding (grants, seed, venture capital, initial public offering, secondary offerings, private equity and debt financing), type of molecule, amount invested, geography, purpose of funding, stage of development, therapeutic area, most active players (in terms of number and amount of funding instances) and leading investors (in terms of number of funding instances).
  • Chapter 13 presents an in-depth analysis of the various next generation RNA therapeutics and RNA vaccines focused initiatives undertaken by big pharma players, based on several relevant parameters, such as number of initiatives, year of initiative, type of initiative, purpose of initiative, focus of initiative and location of headquarters of the big pharma players.
  • Chapter 14 provides a detailed market forecast analysis in order to estimate the existing market size and future opportunity for next generation RNA therapeutics and vaccines, till the year 2035. Based on multiple parameters and likely adoption trends, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The report also features the likely distribution of the current and forecasted opportunity within the RNA therapeutics and RNA vaccines market. Further, in order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry's evolution.
  • Chapter 15 provides detailed projections of the current and future opportunity in the RNA therapeutics and RNA vaccines market across different types of modalities, including therapeutics and vaccines.
  • Chapter 16 provides detailed projections of the current and future opportunity in the RNA therapeutics and RNA vaccines market across different types of molecules, including repRNA, saRNA, sacRNA, samRNA and tRNA.
  • Chapter 17 provides detailed projections of the current and future opportunity in the RNA therapeutics and RNA vaccines market across different therapeutic areas, including infectious diseases, oncological disorders and pulmonary disorders.
  • Chapter 18 provides detailed projections of the current and future opportunity in the RNA therapeutics and RNA vaccines market across different routes of administration, including intradermal, intramuscular and intravenous.
  • Chapter 19 detailed projections of the current and future opportunity in the RNA therapeutics and RNA vaccines market across various geographies, such as North America, Europe, Asia, Latin America, Middle East and North Africa and rest of the world.
  • Chapter 20 provides detailed projections of the current and future opportunity in the RNA therapeutics and RNA vaccines market across the leading players engaged in this domain.
  • Chapter 21 summarizes the entire report, highlighting various facts related to contemporary market trends and the likely evolution of the RNA therapeutics and RNA vaccines market, based on the research and analysis described in the previous chapters.
  • Chapter 22 is an appendix, which contains tabulated data and numbers for all the figures included in this report.
  • Chapter 23 is an appendix, which contains a list of companies and organizations mentioned in this report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. RNA Therapeutics and RNA Vaccines Market Overview
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Research Methodology
  • 1.5. Frequently Asked Questions
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. An Overview of Next Generation RNA Therapeutics and Vaccines
  • 5.2. Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines
  • 5.3. Types of Next Generation RNA Molecules
  • 5.4. Key Aspects of Next Generation RNA Molecules
  • 5.5. Key Challenges Associated with Traditional RNA Modalities
  • 5.6. Advantages of Using Next Generation RNA Modalities

6. MARKET LANDSCAPE

  • 6.1. RNA Therapeutics and RNA Vaccines: Overall Therapies Landscape
    • 6.1.1. Analysis by Type of Modality
    • 6.1.2. Analysis by Type of Molecule
    • 6.1.3. Analysis by Delivery Vehicle
    • 6.1.4. Analysis by Phase of Development
    • 6.1.5. Analysis by Therapeutic Area
    • 6.1.6. Most Active Players: Analysis by Number of Therapies
  • 6.2 RNA Therapeutics and RNA Vaccines: Clinical Stage Therapies Landscape
    • 6.2.1. Analysis by Phase of Development
    • 6.2.2. Analysis by Route of Administration
    • 6.2.3. Analysis by Therapeutic Area
  • 6.3. RNA Therapeutics and RNA Vaccines: Therapy Developers Landscape
    • 6.3.1. Analysis by Year of Establishment
    • 6.3.2. Analysis by Company Size
    • 6.3.3. Analysis by Location of Headquarters
  • 6.4. RNA Therapeutics and RNA Vaccines: Circular RNA Therapies Landscape
    • 6.4.1. Analysis by Phase of Development
    • 6.4.2. Analysis by Therapeutic Area
    • 6.4.3. Most Active Players: Analysis by Number of Therapies
  • 6.5. RNA Therapeutics and RNA Vaccines: Self-amplifying RNA Therapies Landscape
    • 6.5.1. Analysis by Phase of Development
    • 6.5.2. Analysis by Therapeutic Area
    • 6.5.3. Most Active Players: Analysis by Number of Therapies

7. TECHNOLOGY LANDSCAPE

  • 7.1. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technologies Landscape
    • 7.1.1. Analysis by Class of Molecule
    • 7.1.2. Analysis by Type of Molecule
    • 7.1.3. Analysis by Capabilities of the Technology
    • 7.1.4. Analysis by Therapeutic Area
    • 7.1.5. Analysis by Highest Phase of Development
  • 7.2. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technology / Platform Developers Landscape
    • 7.2.1. Analysis by Year of Establishment
    • 7.2.2. Analysis by Company Size
    • 7.2.3. Analysis by Location of Headquarters
    • 7.2.4. Analysis by Operational Model

8. DRUG PROFILES

  • 8.1. Gemcovac
    • 8.1.1. Developer Overview
    • 8.1.2. Drug Overview
    • 8.1.3. Clinical Trial Information
    • 8.1.4. Clinical Trial Endpoints
    • 8.1.5. Clinical Trial Results
    • 8.1.6. Estimated Sales
  • 8.2. ATYR1923
    • 8.2.1. Developer Overview
    • 8.2.2. Drug Overview
    • 8.2.3. Clinical Trial Information
    • 8.2.4. Clinical Trial Endpoints
    • 8.2.5. Clinical Trial Results
    • 8.2.6. Estimated Sales
  • 8.3. ARCT-154
    • 8.3.1. Developer Overview
    • 8.3.2. Drug Overview
    • 8.3.3. Clinical Trial Information
    • 8.3.4. Clinical Trial Endpoints
    • 8.3.5. Clinical Trial Results
    • 8.3.6. Estimated Sales
  • 8.4. GRT-C901
    • 8.4.1. Developer Overview
    • 8.4.2. Drug Overview
    • 8.4.3. Clinical Trial Information
    • 8.4.4. Clinical Trial Endpoints
    • 8.4.5. Clinical Trial Results
    • 8.4.6. Estimated Sales
  • 8.5. VLPCOV-01
    • 8.5.1. Developer Overview
    • 8.5.2. Drug Overview
    • 8.5.3. Estimated Sales
  • 8.6. AVX901
    • 8.6.1. Developer Overview
    • 8.6.2. Drug Overview
    • 8.6.3. Clinical Trial Information
    • 8.6.4. Clinical Trial Endpoints
    • 8.6.5. Clinical Trial Results
    • 8.6.6. Estimated Sales
  • 8.7. MTL-CEBPA + Sorafenib
    • 8.7.1. Developer Overview
    • 8.7.2. Drug Overview
    • 8.7.3. Clinical Trial Information
    • 8.7.4. Clinical Trial Endpoints
    • 8.7.5. Clinical Trial Results
    • 8.7.6. Estimated Sales
  • 8.8. SLATE
    • 8.8.1. Developer Overview
    • 8.8.2. Drug Overview
    • 8.8.3. Clinical Trial Information
    • 8.8.4. Clinical Trial Endpoints
    • 8.8.5. Clinical Trial Results
    • 8.8.6. Estimated Sales

9. CLINICAL TRIAL ANALYSIS

  • 9.1. Analysis Methodology and Key Parameters
  • 9.2. RNA Therapeutics and RNA Vaccines: Clinical Trial Analysis
    • 9.2.1. Analysis by Trial Registration Year
    • 9.2.2. Analysis by Trial Status
    • 9.2.3. Analysis by Trial Registration Year and Trial Status
    • 9.2.4. Analysis by Trial Phase
    • 9.2.5. Analysis by Patients Enrolled
    • 9.2.6. Analysis by Type of Sponsor
    • 9.2.7. Analysis by Therapeutic Area
    • 9.2.8. Analysis by Study Design
    • 9.2.9. Leading Organizations: Analysis by Number of Trials
    • 9.2.10. Analysis by Focus Area
    • 9.2.11. Analysis by Geography

10. PATENT ANALYSIS

  • 10.1. Analysis Methodology and Key Parameters
  • 10.2. RNA Therapeutics and RNA Vaccines: Patent Analysis
    • 10.2.1. Analysis by Type of Patent
    • 10.2.2. Analysis by Patent Publication Year
    • 10.2.3. Analysis by Patent Jurisdiction
      • 10.2.3.1. Analysis by Patent Jurisdiction: North American Scenario
      • 10.2.3.2. Analysis by Patent Jurisdiction: European Scenario
      • 10.2.3.3. Analysis by Patent Jurisdiction: Asia-Pacific Scenario
    • 10.2.4. Analysis by CPC Symbols
    • 10.2.5. World Cloud Analysis: Emerging Focus Areas
    • 10.2.6. Analysis by Patent Age
    • 10.2.7. Leading Industry Players: Analysis by Number of Patents
    • 10.2.8. Leading Non-Industry Players: Analysis by Number of Patents
  • 10.3. RNA Therapeutics and RNA Vaccines: Patent Benchmarking Analysis
  • 10.4. RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis

11. PARTNERSHIPS AND COLLABORATIONS

  • 11.1. Partnership Models
  • 11.2. RNA Therapeutics and RNA Vaccines: Partnerships and Collaborations
    • 11.2.1. Analysis by Year of Partnership
    • 11.2.2. Analysis by Type of Partnership
    • 11.2.3. Analysis by Year and Type of Partnership
    • 11.2.4. Analysis by Year and Type of Molecule
    • 11.2.5. Analysis by Focus of Partnership
    • 11.2.6. Analysis by Purpose of Partnership
    • 11.2.7. Analysis by Therapeutic Area
    • 11.2.8. Most Active Players: Analysis by Number of Partnerships
    • 11.2.9. Analysis by Geography
      • 11.2.9.1. Local and International Agreements
      • 11.2.9.2. Intracontinental and Intercontinental Agreements

12. FUNDING AND INVESTMENT ANALYSIS

  • 12.1. Types of Funding
  • 12.2. RNA Therapeutics and RNA Vaccines: Funding and Investment Analysis
  • 12.3. Analysis by Year of Funding
  • 12.4. Analysis by Type of Funding
  • 12.5. Analysis by Type of Molecule
  • 12.6. Analysis of Amount Invested by Year of Funding
  • 12.7. Analysis of Amount Invested by Type of Funding
  • 12.8. Analysis by Geography
  • 12.9. Analysis by Year and Type of Funding
  • 12.10. Analysis by Purpose of Funding
  • 12.11. Analysis by Stage of Development
  • 12.12. Analysis by Therapeutic Area
  • 12.13. Most Active Players: Analysis by Number of Funding Instances
  • 12.14. Most Active Players: Analysis by Amount Invested
  • 12.15. Leading Investors: Analysis by Number of Funding Instances

13. BIG PHARMA INITIATIVES

  • 13.1. RNA Therapeutics and RNA Vaccines: Big Pharma Initiatives
    • 13.1.1. Analysis by Number of Initiatives
    • 13.1.2. Analysis by Year of Initiative
    • 13.1.3. Analysis by Type of Initiative
      • 13.1.3.1. Analysis by Type of Partnership
      • 13.1.3.2. Analysis by Type of Funding
    • 13.1.4. Analysis by Purpose of Initiative
    • 13.1.5. Analysis by Year and Number of Initiatives
    • 13.1.6. Analysis by Focus of Initiative
    • 13.1.7. Analysis by Location of Headquarters of Big Pharma Players

14. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, 2023-2035

  • 14.1. Key Assumptions and Methodology
  • 14.2. Overall RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035)
    • 14.2.1. Scenario Analysis
  • 14.3. Key Market Segmentations
  • 14.4. Dynamic Dashboard

15. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MODALITY

  • 15.1. Therapeutics: Forecasted Estimates (2023-2035)
  • 15.2. Vaccines: Forecasted Estimates (2023-2035)
  • 15.3. Data Triangulation and Validation

16. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MOLECULE

  • 16.1. repRNA: Forecasted Estimates (2023-2035)
  • 16.2. saRNA: Forecasted Estimates (2023-2035)
  • 16.3. sacRNA: Forecasted Estimates (2023-2035)
  • 16.4. sa-mRNA: Forecasted Estimates (2023-2035)
  • 16.5. tRNA: Forecasted Estimates (2023-2035)
  • 16.6. Data Triangulation and Validation

17. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY THERAPEUTIC AREA

  • 17.1. Infectious Diseases: Forecasted Estimates (2023-2035)
  • 17.2. Oncological Disorders: Forecasted Estimates (2023-2035)
  • 17.3. Pulmonary Disorders: Forecasted Estimates (2023-2035)
  • 17.4. Data Triangulation and Validation

18. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY ROUTE OF ADMINISTRATION

  • 18.1. Intradermal Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
  • 18.2. Intramuscular Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
  • 18.3. Intravenous Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
  • 18.4. Data Triangulation and Validation

19. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 19.1. North America: Forecasted Estimates (2023-2035)
    • 19.1.1. US: Forecasted Estimates (2023-2035)
  • 19.2. Europe: Forecasted Estimates (2023-2035)
    • 19.2.1. France: Forecasted Estimates (2023-2035)
    • 19.2.2. Italy: Forecasted Estimates (2023-2035)
    • 19.2.3. Spain: Forecasted Estimates (2023-2035)
    • 19.2.4. UK: Forecasted Estimates (2023-2035)
    • 19.2.5. The Netherlands: Forecasted Estimates (2023-2035)
  • 19.3. Asia-Pacific: Forecasted Estimates (2023-2035)
    • 19.3.1. India: Forecasted Estimates (2023-2035)
    • 19.3.2. Japan: Forecasted Estimates (2023-2035)
    • 19.3.3. Singapore: Forecasted Estimates (2023-2035)
  • 19.4. Data Triangulation and Validation

20. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY LEADING PLAYERS

  • 20.1. Company A
  • 20.2. Company B
  • 20.3. Company C
  • 20.4. Company D
  • 20.5. Company E

21. CONCLUSION

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 6.1 List of Next Generation RNA Therapeutics and RNA Vaccines
  • Table 6.2 List of Clinical Stage Next Generation RNA Therapeutics and RNA Vaccines
  • Table 6.3 List of Next Generation RNA Therapeutic and RNA Vaccine Developers
  • Table 7.1 List of Next Generation RNA Technologies
  • Table 7.2 List of Next Generation RNA Technology / Platform Developers
  • Table 8.1 Gemcovac®: Developer Overview
  • Table 8.2 Gemcovac®: Drug Overview
  • Table 8.3 Gemcovac®: Clinical Trial Information
  • Table 8.4 Gemcovac®: Clinical Trial Endpoints
  • Table 8.5 Gemcovac®: Clinical Trial Results
  • Table 8.6 ATYR1923: Developer Overview
  • Table 8.7 ATYR1923: Drug Overview
  • Table 8.8 ATYR1923: Clinical Trial Information
  • Table 8.9 ATYR1923: Clinical Trial Endpoints
  • Table 8.10 ATYR1923: Clinical Trial Results
  • Table 8.11 ARCT-154: Developer Overview
  • Table 8.12 ARCT-154: Drug Overview
  • Table 8.13 ARCT-154: Clinical Trial Information
  • Table 8.14 ARCT-154: Clinical Trial Endpoints
  • Table 8.15 ARCT-154: Clinical Trial Results
  • Table 8.16 GRT-C901: Developer Overview
  • Table 8.17 GRT-C901: Drug Overview
  • Table 8.18 GRT-C901: Clinical Trial Information
  • Table 8.19 GRT-C901: Clinical Trial Endpoints
  • Table 8.20 GRT-C901: Clinical Trial Results
  • Table 8.21 VLPCOV-01: Developer Overview
  • Table 8.22 VLPCOV-01: Drug Overview
  • Table 8.23 AVX-901: Developer Overview
  • Table 8.24 AVX-901: Drug Overview
  • Table 8.25 AVX-901: Clinical Trial Information
  • Table 8.26 AVX-901: Clinical Trial Endpoints
  • Table 8.27 AVX-901: Clinical Trial Results
  • Table 8.28 MTL-CEBPA + Sorafenib: Developer Overview
  • Table 8.29 MTL-CEBPA + Sorafenib: Drug Overview
  • Table 8.30 MTL-CEBPA + Sorafenib: Clinical Trial Information
  • Table 8.31 MTL-CEBPA + Sorafenib: Clinical Trial Endpoints
  • Table 8.32 MTL-CEBPA + Sorafenib: Clinical Trial Results
  • Table 8.33 SLATE: Developer Overview
  • Table 8.34 SLATE: Drug Overview
  • Table 8.35 SLATE: Clinical Trial Information
  • Table 8.36 SLATE: Clinical Trial Endpoints
  • Table 8.37 SLATE: Clinical Trial Results
  • Table 9.1 RNA Therapeutics and RNA Vaccines: List of Clinical Trials, Pre-2019-2023
  • Table 10.1 RNA Therapeutics and RNA Vaccines: List of Filed / Granted Patents, 2019-2023
  • Table 11.1 RNA Therapeutics and RNA Vaccines: List of Partnerships and Collaborations, 2019-2023
  • Table 12.1 RNA Therapeutics and RNA Vaccines: List of Funding and Investments, 2019-2023
  • Table 13.1 RNA Therapeutics and RNA Vaccines: List of Big Pharma Initiatives, 2019-2023
  • Table 14.1 RNA Therapeutics and RNA Vaccines Market: Expected Launch Year of Forecasted Drug Candidates
  • Table 22.1 Next Generation RNA Therapies: Distribution by Type of Modality
  • Table 22.2 Next Generation RNA Therapies: Distribution by Type of Molecule
  • Table 22.3 Next Generation RNA Therapies: Distribution by Delivery Vehicle
  • Table 22.4 Next Generation RNA Therapies: Distribution by Phase of Development
  • Table 22.5 Next Generation RNA Therapies: Distribution by Therapeutic Area
  • Table 22.6 Most Active Players: Distribution by Number of Therapies
  • Table 22.7 Clinical Stage Therapies: Distribution by Phase of Development
  • Table 22.8 Clinical Stage Therapies: Distribution by Route of Administration
  • Table 22.9 Clinical Stage Therapies: Distribution by Therapeutic Area
  • Table 22.10 Therapy Developer Landscape: Distribution by Year of Establishment
  • Table 22.11 Therapy Developer Landscape: Distribution by Company Size
  • Table 22.12 Therapy Developer Landscape: Distribution by Location of Headquarters
  • Table 22.13 circRNA Therapies: Distribution by Phase of Development
  • Table 22.14 circRNA Therapies: Distribution by Therapeutic Area
  • Table 22.15 Most Active Players: Distribution by Number of circRNA Therapies
  • Table 22.16 saRNA Therapies: Distribution by Phase of Development
  • Table 22.17 saRNA Therapies: Distribution by Therapeutic Area
  • Table 22.18 Most Active Players: Distribution by Number of saRNA Therapies
  • Table 22.19 Next Generation RNA Technologies: Distribution by Class of Molecule
  • Table 22.20 Next Generation RNA Technologies: Distribution by Type of Molecule
  • Table 22.21 Next Generation RNA Technologies: Distribution by Capabilities of the Technology
  • Table 22.22 Next Generation RNA Technologies: Distribution by Therapeutic Area
  • Table 22.23 Next Generation RNA Technologies: Distribution by Highest Phase of Development
  • Table 22.24 Technology Developer Landscape: Distribution by Year of Establishment
  • Table 22.25 Technology Developer Landscape: Distribution by Company Size
  • Table 22.26 Technology Developer Landscape: Distribution by Location of Headquarters
  • Table 22.27 Technology Developer Landscape: Distribution by Operational Model
  • Table 22.28 Gemcovac®: Estimated Sales
  • Table 22.29 ATYR1923: Estimated Sales
  • Table 22.30 ARCT-154: Estimated Sales
  • Table 22.31 GRT-C901: Estimated Sales
  • Table 22.32 VLPCOV-01: Estimated Sales
  • Table 22.33 AVX901: Estimated Sales
  • Table 22.34 MTL-CEBPA + Sorafenib: Estimated Sales
  • Table 22.35 SLATE: Estimated Sales
  • Table 22.36 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2019-2023
  • Table 22.37 Clinical Trial Analysis: Distribution by Trial Status
  • Table 22.38 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2019-2022
  • Table 22.39 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 22.40 Clinical Trial Analysis: Distribution by Patients Enrolled
  • Table 22.41 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Table 22.42 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Table 22.43 Clinical Trial Analysis: Distribution by Study Design
  • Table 22.44 Leading Organizations: Distribution by Number of Trials
  • Table 22.45 Clinical Trial Analysis: Distribution by Focus Area
  • Table 22.46 Clinical Trial Analysis: Distribution by Geography
  • Table 22.47 Patent Analysis: Distribution by Type of Patent
  • Table 22.48 Patent Analysis: Cumulative Year-wise Trend, 2019-2023
  • Table 22.49 Patent Analysis: Distribution by Patent Jurisdiction
  • Table 22.50 Patent Jurisdiction: North American Scenario
  • Table 22.51 Patent Jurisdiction: European Scenario
  • Table 22.52 Patent Jurisdiction: Aisa-Pacific Scenario
  • Table 22.53 Patent Analysis: Distribution by Patent Age
  • Table 22.54 Patent Analysis: Distribution by CPC Symbols
  • Table 22.55 Leading Industry Players: Distribution by Number of Patents
  • Table 22.56 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 22.57 Patent Analysis: Distribution by Patent Characteristics
  • Table 22.58 RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis
  • Table 22.59 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
  • Table 22.60 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 22.61 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2019-2023
  • Table 22.62 Partnerships and Collaborations: Distribution by Year and Type of Molecule, 2019-2023
  • Table 22.63 Partnerships and Collaborations: Distribution by Focus of Partnership
  • Table 22.64 Partnerships and Collaborations: Distribution by Purpose of Partnership
  • Table 22.65 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 22.66 Most Active Players: Distribution by Number of Partnerships
  • Table 22.67 Partnerships and Collaborations: Local and International Deals
  • Table 22.68 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Table 22.69 Funding and Investment Analysis: Cumulative Year-wise Trend, 2019-2023
  • Table 22.70 Funding and Investment Analysis: Distribution by Type of Funding
  • Table 22.71 Funding and Investment Analysis: Distribution by Type of Molecule
  • Table 22.72 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2019-2023 (USD Million)
  • Table 22.73 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 22.74 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
  • Table 22.75 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2019-2023
  • Table 22.76 Funding and Investment Analysis: Distribution by Purpose of Funding
  • Table 22.77 Funding and Investment Analysis: Distribution by Stage of Development
  • Table 22.78 Funding and Investment Analysis: Distribution by Therapeutic Area
  • Table 22.79 Most Active Players: Distribution by Number of Funding Instances
  • Table 22.80 Most Active Players: Distribution by Amount Invested (USD Million)
  • Table 22.81 Leading Investors: Distribution by Number of Funding Instances
  • Table 22.82 Big Pharma Initiatives: Distribution by Number of Initiatives
  • Table 22.83 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative, 2019-2023
  • Table 22.84 Big Pharma Initiatives: Distribution by Type of Initiative
  • Table 22.85 Big Pharma Initiatives: Cumulative Distribution by Purpose of Initiative
  • Table 22.86 Big Pharma Initiatives: Cumulative Year-wise Trend, 2019-2023
  • Table 22.87 Big Pharma Initiatives: Distribution by Focus of Initiative
  • Table 22.88 Big Pharma Initiatives: Distribution by Location of Headquarters of Big Pharma Players
  • Table 22.89 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Base Scenario (USD Million)
  • Table 22.90 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Million)
  • Table 22.91 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Million)
  • Table 22.92 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Modality, 2023, 2028 and 2035 (USD Million)
  • Table 22.93 Global RNA Therapeutics Market, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.94 Global RNA Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.95 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Molecule, 2023, 2028 and 2035 (USD Million)
  • Table 22.96 Global repRNA Therapeutics Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.97 Global saRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.98 Global sacRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.99 Global sa-mRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.100 Global tRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.101 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Therapeutic Area, 2023, 2028 and 2035 (USD Million)
  • Table 22.102 Global RNA Therapeutics and RNA Vaccines Market for Infectious Diseases, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.103 Global RNA Therapeutics and RNA Vaccines Market for Oncological Disorders, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.104 Global RNA Therapeutics and RNA Vaccines Market for Pulmonary Disorders, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.105 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Route of Administration, 2023, 2028 and 2035 (USD Million)
  • Table 22.106 Global RNA Therapeutics and RNA Vaccines Market for Intradermal Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.107 Global RNA Therapeutics and RNA Vaccines Market for Intramuscular Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.108 Global RNA Therapeutics and RNA Vaccines Market for Intravenous Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.109 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Million)
  • Table 22.110 RNA Therapeutics and RNA Vaccines Market in North America, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.111 RNA Therapeutics and RNA Vaccines Market in the US, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.112 RNA Therapeutics and RNA Vaccines Market in Europe, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.113 RNA Therapeutics and RNA Vaccines Market in France, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.114 RNA Therapeutics and RNA Vaccines Market in Italy, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.115 RNA Therapeutics and RNA Vaccines Market in Spain, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.116 RNA Therapeutics and RNA Vaccines Market in the UK, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.117 RNA Therapeutics and RNA Vaccines Market in the Netherlands, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.118 RNA Therapeutics and RNA Vaccines Market in Asia-Pacific, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.119 RNA Therapeutics and RNA Vaccines Market in India, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.120 RNA Therapeutics and RNA Vaccines Market in Japan, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.121 RNA Therapeutics and RNA Vaccines Market in Singapore, Forecasted Estimates (2023-2035) (USD Million)
  • Table 22.122 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Leading Players, 2023, 2028 and 2035 (USD Million)

List of Figures

  • Figure 4.1 Executive Summary: Overall Market Landscape
  • Figure 4.2 Executive Summary: Overall Technology Landscape
  • Figure 4.3 Executive Summary: Clinical Trial Analysis
  • Figure 4.4 Executive Summary: Patent Analysis
  • Figure 4.5 Executive Summary: Partnerships and Collaborations
  • Figure 4.6 Executive Summary: Funding and Investment Analysis
  • Figure 4.7 Executive Summary: Big Pharma Initiatives
  • Figure 4.8 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 5.1 Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines
  • Figure 5.2 Key Aspects of Next Generation RNA Molecules
  • Figure 5.3 Key Challenges Associated with Traditional RNA Modalities
  • Figure 5.4 Advantages of Using Next Generation RNA Modalities
  • Figure 6.1 Next Generation RNA Therapies: Distribution by Type of Modality
  • Figure 6.2 Next Generation RNA Therapies: Distribution by Type of Molecule
  • Figure 6.3 Next Generation RNA Therapies: Distribution by Delivery Vehicle
  • Figure 6.4 Next Generation RNA Therapies: Distribution by Phase of Development
  • Figure 6.5 Next Generation RNA Therapies: Distribution by Therapeutic Area
  • Figure 6.6 Most Active Players: Distribution by Number of Therapies
  • Figure 6.7 Clinical Stage Therapies: Distribution by Phase of Development
  • Figure 6.8 Clinical Stage Therapies: Distribution by Route of Administration
  • Figure 6.9 Clinical Stage Therapies: Distribution by Therapeutic Area
  • Figure 6.10 Therapy Developer Landscape: Distribution by Year of Establishment
  • Figure 6.11 Therapy Developer Landscape: Distribution by Company Size
  • Figure 6.12 Therapy Developer Landscape: Distribution by Location of Headquarters
  • Figure 6.13 circRNA Therapies: Distribution by Phase of Development
  • Figure 6.14 circRNA Therapies: Distribution by Therapeutic Area
  • Figure 6.15 Most Active Players: Distribution by Number of circRNA Therapies
  • Figure 6.16 saRNA Therapies: Distribution by Phase of Development
  • Figure 6.17 saRNA Therapies: Distribution by Therapeutic Area
  • Figure 6.18 Most Active Players: Distribution by Number of saRNA Therapies
  • Figure 7.1 Next Generation RNA Technologies: Distribution by Class of Molecule
  • Figure 7.2 Next Generation RNA Technologies: Distribution by Type of Molecule
  • Figure 7.3 Next Generation RNA Technologies: Distribution by Capabilities of the Technology
  • Figure 7.4 Next Generation RNA Technologies: Distribution by Therapeutic Area
  • Figure 7.5 Next Generation RNA Technologies: Distribution by Highest Phase of Development
  • Figure 7.6 Technology Developer Landscape: Distribution by Year of Establishment
  • Figure 7.7 Technology Developer Landscape: Distribution by Company Size
  • Figure 7.8 Technology Developer Landscape: Distribution by Location of Headquarters
  • Figure 7.9 Technology Developer Landscape: Distribution by Operational Model
  • Figure 8.1 Gemcovac®: Estimated Sales
  • Figure 8.2 ATYR1923: Estimated Sales
  • Figure 8.3 ARCT-154: Estimated Sales
  • Figure 8.4 GRT-C901: Estimated Sales
  • Figure 8.5 VLPCOV-01: Estimated Sales
  • Figure 8.6 AVX901: Estimated Sales
  • Figure 8.7 MTL-CEBPA + Sorafenib: Estimated Sales
  • Figure 8.8 SLATE: Estimated Sales
  • Figure 9.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2019-2023
  • Figure 9.2 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 9.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2019-2022
  • Figure 9.4 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 9.5 Clinical Trial Analysis: Distribution by Patients Enrolled
  • Figure 9.6 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Figure 9.7 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Figure 9.8 Clinical Trial Analysis: Distribution by Study Design
  • Figure 9.9 Leading Organizations: Distribution by Number of Trials
  • Figure 9.10 Clinical Trial Analysis: Distribution by Focus Area
  • Figure 9.11 Clinical Trial Analysis: Distribution by Geography
  • Figure 10.1 Patent Analysis: Distribution by Type of Patent
  • Figure 10.2 Patent Analysis: Cumulative Year-wise Trend, 2019-2023
  • Figure 10.3 Patent Analysis: Distribution by Patent Jurisdiction
  • Figure 10.4 Patent Jurisdiction: North American Scenario
  • Figure 10.5 Patent Jurisdiction: European Scenario
  • Figure 10.6 Patent Jurisdiction: Aisa-Pacific Scenario
  • Figure 10.7 Patent Analysis: Distribution by Patent Age
  • Figure 10.8 Patent Analysis: Distribution by CPC Symbols
  • Figure 10.9 Word Cloud Analysis: Emerging Focus Areas
  • Figure 10.10 Leading Industry Players: Distribution by Number of Patents
  • Figure 10.11 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 10.12 Patent Analysis: Distribution by Patent Characteristics
  • Figure 10.13 RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis
  • Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
  • Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2019-2023
  • Figure 11.4 Partnerships and Collaborations: Distribution by Year and Type of Molecule, 2019-2023
  • Figure 11.5 Partnerships and Collaborations: Distribution by Focus of Partnership
  • Figure 11.6 Partnerships and Collaborations: Distribution by Purpose of Partnership
  • Figure 11.7 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 11.8 Most Active Players: Distribution by Number of Partnerships
  • Figure 11.9 Partnerships and Collaborations: Local and International Deals
  • Figure 11.10 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2019-2023
  • Figure 12.2 Funding and Investment Analysis: Distribution by Type of Funding
  • Figure 12.3 Funding and Investment Analysis: Distribution by Type of Molecule
  • Figure 12.4 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2019-2023 (USD Million)
  • Figure 12.5 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 12.6 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million
  • Figure 12.7 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2019-2023
  • Figure 12.8 Funding and Investment Analysis: Distribution by Purpose of Funding
  • Figure 12.9 Funding and Investment Analysis: Distribution by Stage of Development
  • Figure 12.10 Funding and Investment Analysis: Distribution by Therapeutic Area
  • Figure 12.11 Most Active Players: Distribution by Number of Funding Instances
  • Figure 12.12 Most Active Players: Distribution by Amount Invested (USD Million)
  • Figure 12.13 Leading Investors: Distribution by Number of Funding Instances
  • Figure 13.1 Big Pharma Initiatives: Distribution by Number of Initiatives
  • Figure 13.2 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative
  • Figure 13.3 Big Pharma Initiatives: Distribution by Type of Initiative
  • Figure 13.4 Big Pharma Initiatives: Cumulative Distribution by Purpose of Initiative
  • Figure 13.5 Big Pharma Initiatives: Cumulative Year-wise Trend, 2019-2023
  • Figure 13.6 Big Pharma Initiatives: Distribution by Focus of Initiative
  • Figure 13.7 Big Pharma Initiatives: Distribution by Location of Headquarters of Big Pharma Players
  • Figure 14.1 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Base Scenario (USD Million)
  • Figure 14.2 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Million)
  • Figure 14.3 Global RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Million)
  • Figure 15.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Modality, 2023, 2028 and 2035 (USD Million)
  • Figure 15.2 Global RNA Therapeutics Market, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 15.3 Global RNA Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 16.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Type of Molecule, 2023, 2028 and 2035 (USD Million)
  • Figure 16.2 Global repRNA Therapeutics Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 16.3 Global saRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 16.4 Global sacRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 16.5 Global sa-mRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 16.6 Global tRNA Therapeutics and Vaccines Market, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 17.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Therapeutic Area, 2023, 2028 and 2035 (USD Million)
  • Figure 17.2 Global RNA Therapeutics and RNA Vaccines Market for Infectious Diseases, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 17.3 Global RNA Therapeutics and RNA Vaccines Market for Oncological Disorders, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 17.4 Global RNA Therapeutics and RNA Vaccines Market for Pulmonary Disorders, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 18.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Route of Administration, 2023, 2028 and 2035 (USD Million)
  • Figure 18.2 Global RNA Therapeutics and RNA Vaccines Market for Intradermal Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 18.3 Global RNA Therapeutics and RNA Vaccines Market for Intramuscular Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 18.4 Global RNA Therapeutics and RNA Vaccines Market for Intravenous Therapeutics / Vaccines, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.1 Global RNA Therapeutics and RNA Vaccines Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Million)
  • Figure 19.2 RNA Therapeutics and RNA Vaccines Market in North America, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.3 RNA Therapeutics and RNA Vaccines Market in the US, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.4 RNA Therapeutics and RNA Vaccines Market in Europe, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.5 RNA Therapeutics and RNA Vaccines Market in France, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.6 RNA Therapeutics and RNA Vaccines Market in Italy, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.7 RNA Therapeutics and RNA Vaccines Market in Spain, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.8 RNA Therapeutics and RNA Vaccines Market in the UK, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.9 RNA Therapeutics and RNA Vaccines Market in the Netherlands, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.10 RNA Therapeutics and RNA Vaccines Market in Asia-Pacific, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.11 RNA Therapeutics and RNA Vaccines Market in India, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.12 RNA Therapeutics and RNA Vaccines Market in Japan, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 19.13 RNA Therapeutics and RNA Vaccines Market in Singapore, Forecasted Estimates (2023-2035) (USD Million)
  • Figure 20.1 RNA Therapeutics and RNA Vaccines Market: Distribution by Leading Players, 2023, 2028 and 2035 (USD Million)